Patents by Inventor Tacey X. Viegas
Tacey X. Viegas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140045770Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the small molecule drug not attached to the water-soluble oligomer.Type: ApplicationFiled: October 16, 2013Publication date: February 13, 2014Applicant: NEKTAR THERAPEUTICSInventors: Jennifer RIGGS-SAUTHIER, Lin Cheng, Tacey X. Viegas, Xuyuan Gu, Franco J. Duarte, Wen Zhang
-
Patent number: 8598364Abstract: The invention provides protease inhibitors that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the protease inhibitors not attached to the water-soluble oligomer.Type: GrantFiled: March 12, 2008Date of Patent: December 3, 2013Assignee: Nektar TherapeuticsInventors: Jennifer Riggs-Sauthier, Lin Cheng, Tacey X. Viegas, Xuyuan Gu, Franco J. Duarte, Wen Zhang
-
Patent number: 8580919Abstract: Conjugates of a GLP-1 moiety may be covalently attached to one or more water-soluble polymers. For instance, a GLP-1 polymer conjugate may include a GLP-1 moiety releasably attached at its N-terminus to a water-soluble polymer. The GLP-1 polymer conjugate may include a GLP-1 moiety covalently attached to a water-soluble polymer, wherein the GLP-1 moiety possesses an N-methyl substituent.Type: GrantFiled: September 14, 2012Date of Patent: November 12, 2013Assignee: Nektar TherapeuticsInventors: Mary J. Bossard, Zhihao Fang, Tacey X. Viegas, Stewart A. Thompson, Mei-chang Kuo
-
Publication number: 20130096258Abstract: Conjugates of a GLP-1 moiety may be covalently attached to one or more water-soluble polymers. For instance, a GLP-1 polymer conjugate may include a GLP-1 moiety releasably attached at its N-terminus to a water-soluble polymer. The GLP-1 polymer conjugate may include a GLP-1 moiety covalently attached to a water-soluble polymer, wherein the GLP-1 moiety possesses an N-methyl substituent.Type: ApplicationFiled: September 14, 2012Publication date: April 18, 2013Applicant: Nektar TherapeuticsInventors: Mary J. BOSSARD, Zhihao Fang, Tacey X. Viegas, Stewart A. Thompson, Mei-chang Kuo
-
Patent number: 8394365Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.Type: GrantFiled: November 30, 2007Date of Patent: March 12, 2013Assignee: Nektar TherapeuticsInventors: Xuan Zhao, Michael David Bentley, Zhongxu Ren, Tacey X. Viegas
-
Publication number: 20130053400Abstract: The invention provides antihistamine drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the antihistamine drug not attached to the water-soluble oligomer.Type: ApplicationFiled: September 7, 2012Publication date: February 28, 2013Applicant: Nektar TherapeuticsInventors: Jennifer Riggs-Sauthier, Wen Zhang, Tacey X. Viegas, Michael D. Bentley
-
Patent number: 8318145Abstract: Provided herein are water-soluble prodrugs. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.Type: GrantFiled: March 19, 2010Date of Patent: November 27, 2012Assignee: Nektar TherapeuticsInventors: Xuan Zhao, Michael D. Bentley, Zhongxu Ren, Tacey X. Viegas
-
Patent number: 8293869Abstract: Conjugates of a GLP-I moiety may be covalently attached to one or more water-soluble polymers. For instance, a GLP-I polymer conjugate may include a GLP-I moiety releasably attached at its N-terminus to a water-soluble polymer. The GLP-I polymer conjugate may include a GLP-I moiety covalently attached to a water-soluble polymer, wherein the GLP-I moiety possesses an N-methyl substituent. The GLP-I polymer conjugate may include a GLP-I moiety covalently attached at a polymer attachment site to a water-soluble polymer, wherein the GLP-I moiety is glycosylated at a site separate from the polymer attachment site.Type: GrantFiled: December 18, 2006Date of Patent: October 23, 2012Assignee: Nektar TherapeuticsInventors: Mary J. Bossard, Zhihao Fang, Tacey X. Viegas, Stewart A. Thompson, Mei-chang Kuo
-
Patent number: 8263062Abstract: Provided herein are water-soluble prodrugs. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.Type: GrantFiled: February 22, 2010Date of Patent: September 11, 2012Assignee: Nektar TherapeuticsInventors: Xuan Zhao, Michael D. Bentley, Zhongxu Ren, Tacey X. Viegas
-
Publication number: 20110269677Abstract: The invention provides protease inhibitors that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the protease inhibitors not attached to the water-soluble oligomer.Type: ApplicationFiled: March 12, 2008Publication date: November 3, 2011Applicant: Nektar TherapeuticsInventors: Jennifer Riggs-Sauthier, Lin Cheng, Tacey X. Viegas, Xuyuan Gu, Franco J. Duarte, Wen Zhang
-
Patent number: 8034825Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer obtained from a monodisperse or bimodal water-soluble oligomer composition. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.Type: GrantFiled: June 24, 2010Date of Patent: October 11, 2011Assignee: Nektar TherapeuticsInventors: Michael D. Bentley, Tacey X. Viegas, Richard R. Goodin, Lin Cheng, Xuan Zhao
-
Patent number: 7786133Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer obtained from a monodisperse or bimodal water-soluble oligomer composition. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.Type: GrantFiled: December 16, 2004Date of Patent: August 31, 2010Assignee: Nektar TherapeuticsInventors: Michael D. Bentley, Tacey X. Viegas, Richard R. Goodin, Lin Cheng, Xuan Zhao
-
Publication number: 20100210505Abstract: Conjugates of a GLP-I moiety may be covalently attached to one or more water-soluble polymers. For instance, a GLP-I polymer conjugate may include a GLP-I moiety releasably attached at its N-terminus to a water-soluble polymer. The GLP-I polymer conjugate may include a GLP-I moiety covalently attached to a water-soluble polymer, wherein the GLP-I moiety possesses an N-methyl substituent. The GLP-I polymer conjugate may include a GLP-I moiety covalently attached at a polymer attachment site to a water-soluble polymer, wherein the GLP-I moiety is glycosylated at a site separate from the polymer attachment site.Type: ApplicationFiled: December 18, 2006Publication date: August 19, 2010Applicants: Nektar Therapeutics AL, Corporation, Nektar TherapeuticsInventors: Mary J. Bossard, Zhihao Fang, Tacey X. Viegas, Stewart A. Thompson, Mei-chang Kuo
-
Publication number: 20100190933Abstract: Provided herein are water-soluble prodrugs. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.Type: ApplicationFiled: March 19, 2010Publication date: July 29, 2010Applicant: Nektar TherapeuticsInventors: Xuan Zhao, Michael D. Bentley, Zhongxu Ren, Tacey X. Viegas
-
Patent number: 7744861Abstract: Provided herein are water-soluble prodrugs. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.Type: GrantFiled: September 17, 2004Date of Patent: June 29, 2010Assignee: Nektar TherapeuticsInventors: Xuan Zhao, Michael D. Bentley, Zhongxu Ren, Tacey X. Viegas
-
Publication number: 20100152201Abstract: The invention provides antihistamine drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the antihistamine drug not attached to the water-soluble oligomer.Type: ApplicationFiled: March 12, 2008Publication date: June 17, 2010Applicant: Nektar TherapeuticsInventors: Jennifer Riggs-Sauthier, Wen Zhang, Tacey X Viegas, Michael D Bentley
-
Publication number: 20100152414Abstract: Provided herein are water-soluble prodrugs. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.Type: ApplicationFiled: February 22, 2010Publication date: June 17, 2010Applicant: Nektar TherapeuticsInventors: Xuan Zhao, Michael D. Bentley, Zhongxu Ren, Tacey X. Viegas
-
Publication number: 20090074704Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.Type: ApplicationFiled: November 30, 2007Publication date: March 19, 2009Applicant: Nektar Therapeutics AL, CorporationInventors: Xuan Zhao, Michael David Bentley, Zhongxu Ren, Tacey X. Viegas
-
Publication number: 20080194612Abstract: Provided herein are water-soluble prodrugs. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.Type: ApplicationFiled: February 11, 2008Publication date: August 14, 2008Applicant: Nektar Therapeutics AL, CorporationInventors: Xuan Zhao, Michael D. Bentley, Zhongxu Ren, Tacey X. Viegas
-
Publication number: 20030143274Abstract: Balanced pH, hyperosmotic, hypoosmotic, or isoosmotic gels are ideal vehicles for drug delivery. They are especially suited for topical body cavity or injection application of drugs or diagnostic agents; for drug or diagnostic agent delivery to the eye of a mammal; as protective corneal shields; or as ablatable corneal masks useful in laser reprofiling of the cornea. The compositions without the addition of a drug or diagnostic agent are useful as medical devices, for instance, in separating surgically or otherwise injured tissue as a means of preventing adhesions.Type: ApplicationFiled: September 4, 2002Publication date: July 31, 2003Inventors: Tacey X. Viegas, Lorraine E. Reeve, Raymond L. Henry